NZ’s most ambitious health IT company built 65% of its revenue from North America, rode the Obama-era digital health wave to a billion-dollar NZX listing, then nearly went bankrupt before its founder put his own money in to keep it alive. The capital structure was wrong from the start.
Founded in Auckland in 1993 by Ian McCrae, Orion Health spent two decades building health IT infrastructure — clinical workflow software, health information exchanges, and interoperability platforms — for hospitals, governments, and insurers across the English-speaking world. By the time it listed on the NZX and ASX in November 2014, 65% of its revenue came from North America. The US was not a market Orion was entering. It was the market Orion had already built its business around.
The company was founded on a genuine insight: healthcare is drowning in data that cannot talk to itself. Different hospitals run different systems. Different insurers require different formats. Different government agencies mandate different standards. Orion built the connective tissue — software that made disparate health systems legible to each other. In New Zealand, Australia, and the UK, that proposition had won them government contracts and a growing enterprise base. In the US, the timing appeared perfect.
The Obama administration’s Health Information Technology for Economic and Clinical Health (HITECH) Act of 2009 committed US$30 billion to digitise American healthcare records. McCrae was explicit about what that meant for Orion: he expected to be “well placed to benefit from the surge in government spending.” The company was widely described as “the next Xero.” McCrae talked publicly about reaching $1 billion in annual turnover. The IPO raised NZ$125 million. The market cap briefly hit NZ$1 billion.
The thesis was not unreasonable. US healthcare was fragmented, under-digitised, and being pushed toward interoperability by federal mandate. Orion had the product — a battle-tested clinical platform already running in some of the world’s most demanding health systems. It had the relationships, built over years of enterprise sales. And it had a policy tailwind that was, for a brief moment, blowing in exactly the right direction.
What McCrae called a “perfect storm” on the way down had, for a time, looked like a perfect alignment on the way up: federal money flowing, hospitals buying, and a NZ company sitting at the centre of it. The structural error wasn’t the thesis. It was the capital plan attached to it — and the failure to model what would happen if the policy environment shifted, the sales cycles lengthened, or the cloud migration burned more cash than projected.
November 2014: IPO on NZX/ASX raising NZ$125 million at $5.70 per share. Market cap briefly reaches NZ$1 billion. 65% of revenue from North America. 1,250 staff globally. US operations initially run from a rented house in Santa Monica. McCrae publicly targets $1 billion in annual turnover, citing the Obama-era HITECH spending wave as the primary growth driver.
FY2015: Net loss of NZ$60.8 million against a prior year loss of just $1.1 million — a 5,427% deterioration in twelve months. US perpetual licence revenue drops 81%. The company blames “contract delays” in large US health organisations. Analysts begin questioning the guidance model. By March 2017, only NZ$6 million in cash remains after NZ$51.5 million in net outflows. McCrae injects his own money via an emergency NZ$32.9 million rights issue. Staff are cut from 1,250 to 560. July 2018: Orion sells its most profitable business unit — the Rhapsody integration engine — to UK private equity firm Hg for NZ$205 million, described by analysts as selling the golden goose to keep the rest of the farm. March 2019: McCrae takes the company private at NZ$1.224 per share — 79% below the IPO price.
“Orion Health leaves a stain on the market. For investors the outcome is really only one step up from receivership.”
— Anonymous investor, NZ Herald, 2019
Orion Health did not fail because the product was technically inferior or because the US healthcare market was inaccessible. It failed because four structural decisions — made before and during the expansion — created compounding liabilities that became fatal when the policy environment shifted and the capital ran out. Each was individually survivable. Together, they were not.
Orion raised NZ$125 million at IPO. That sounds substantial until you compare it to the companies it was competing against. Epic Systems — the dominant US electronic health records platform — was generating over US$3 billion in annual revenue by the mid-2010s. Cerner, the second major player, was generating over US$2 billion. Both had decades of US hospital relationships, certified integration stacks, and sales teams measured in the hundreds.
Orion was simultaneously funding a cloud migration, maintaining a global sales operation, and trying to win US government health IT contracts against companies with 10–20x its annual revenue. The NZ$125 million IPO raise was not seed capital for a US entry. It was a NZ-scale public market raise applied to a US-scale competitive battle. The two were structurally incompatible from day one.
The deeper problem was what the capital was being asked to do concurrently. Orion was not just entering the US — it was rebuilding its entire product stack from on-premise perpetual licences to cloud subscription SaaS while trying to win new enterprise contracts in a market that required referenceable US deployments to close new US deals. Three capital-intensive activities running simultaneously, funded by a single raise that had been sized against NZ investor expectations, not US competitive realities.
Craigs Investment Partners called management “consistently over-optimistic.” That is a polite way of saying the capital plan assumed everything went right. US market entry plans need to assume nothing goes right.
Orion’s US growth strategy was structurally dependent on a single policy bet: that the Obama administration’s HITECH spending would translate into sustained, predictable contract revenue for health IT vendors. When Donald Trump was elected in November 2016 and the Affordable Care Act came under immediate political attack, the downstream effect on health IT spending was swift. MobiHealthNews reported that Orion had to restructure “as a result of the Trump administration’s decision to cancel several Obamacare contracts.”
This is not a Trump problem. It is a structural design problem. A US entry architecture that depends on a specific administration’s policy priorities being sustained is not an architecture. It is a bet. NZ companies entering the US through government-adjacent channels — healthcare, defence, infrastructure, education — must model the business under both the favourable and the unfavourable policy scenario before capital is committed. Orion modelled one scenario and built a public company around it.
McCrae’s response to the FY2015 loss of NZ$60.8 million was to describe it as a “perfect storm.” The phrase is revealing. A perfect storm is an event that could not have been predicted. The political fragility of Obama-era health spending was not unpredictable — it was a known political risk that any serious US market entry analysis should have stress-tested.
McCrae repeatedly cited “contract delays” as the primary explanation for missed forecasts. In FY2015, in FY2016, in FY2017 — the same explanation, the same framing: the contracts were there, they were just taking longer to close than expected. Analysts at Forsyth Barr eventually declared the company “running on empty” with a trajectory that was “not sustainable.”
The “contract delays” explanation was not wrong — it was incomplete. US enterprise healthcare is structurally the most complex B2B sales environment in existence. A health information exchange contract with a large, often state-owned or state-adjacent health organisation involves procurement committees, legal review, security certification, integration testing, pilot deployment, budget approval cycles tied to government fiscal years, and political sign-off at the executive level. A deal that a NZ-trained sales leader might model as a six-month close is realistically an 18–36 month process in a US public health context.
This is not a delay. It is the market structure. Building a financial model — and a public company guidance regime — that treats the inherent cycle length of US enterprise health IT sales as temporary friction is not an execution problem. It is a design problem that should have been identified before the IPO roadshow.
The result was a company that kept telling investors the revenue was “coming” through multiple consecutive earnings periods, burning cash against a pipeline that was real but measured in years rather than quarters, until the cash ran out before the contracts closed.
Orion’s US strategy at IPO was predicated on winning new cloud-based contract revenue — but the product being sold was still substantially on-premise perpetual licence software. The company was simultaneously trying to win US customers with a cloud value proposition while rebuilding the underlying product architecture to deliver it. These are two separate capital and execution problems. Running them concurrently, funded by a single public raise, created a situation where neither could be done well.
The 81% drop in US perpetual licence revenue in FY2015 was not purely a market problem. Part of it was a product transition problem: customers who might have bought the on-premise product were waiting for the cloud version; customers evaluating the cloud version were encountering a product that wasn’t fully there yet. Orion was caught between two generations of its own product at the moment it most needed a clean, credible US sales story.
The correct sequence would have been to complete the cloud migration to a commercially deployable state before going to public markets on the back of a US growth story. Doing it in the other order — raising public capital on a cloud growth narrative before the cloud product was ready — created a credibility gap with US customers and an expectation gap with NZ investors that the company spent five years trying to close.
THE CAPITAL PROBLEM
Cash remaining at Orion Health in March 2017 — three years after raising NZ$125M at IPO
After NZ$51.5 million in net outflows, the company was weeks from insolvency. McCrae injected his own money via an emergency rights issue. The IPO capital had not been sized for the US battle it was funding.
FAILURE DIMENSION ANALYSIS — ORION HEALTH
The rights issue was the moment Orion’s US expansion became irreversible in the wrong direction. With NZ$6 million in cash and NZ$51.5 million in outflows already recorded, the company had two options: find new capital or sell assets. McCrae chose both — he put in NZ$32.9 million of his own money, then sold Rhapsody — the integration engine that was generating reliable recurring revenue — to UK private equity for NZ$205 million.
The Rhapsody sale was the tell. When a company sells its most profitable business unit to fund the rest of the operation, it has stopped growing and started surviving. The NZ$205 million from Hg bought time, but it also removed the highest-quality revenue stream from the business, making the remaining Orion Health less valuable, less fundable, and less credible to US enterprise buyers evaluating a long-term vendor relationship.
McCrae took the company private at NZ$1.224 per share in March 2019. Shareholders who bought at IPO received 21 cents on the dollar. The company that was going to be the next Xero had destroyed approximately NZ$70 million in net losses and been sold to its own founder below any reasonable measure of its IPO value.
Orion Health’s US strategy was sound in concept and fatally miscalibrated in execution. The US healthcare interoperability market was and is a real market. The HITECH stimulus was real money. The clinical platform was genuinely differentiated. None of that matters if the capital plan cannot sustain the competitive battle, the revenue model cannot survive a policy change, and the sales cycle assumptions cannot survive contact with a US enterprise procurement process.
The company went to public markets with a US growth story before the US product, US capital position, and US sales model were ready to support that story. The IPO locked in a set of investor expectations that the underlying business — in the actual US healthcare market conditions of 2015–2019 — could not meet. Every year of “contract delays” was a year of burning capital against a timeline that investors thought was months and the market had priced as years.
If your US revenue strategy depends on a government policy staying in place, model the business without that policy before you commit capital. The political durability of any US administration’s spending priorities is not a planning assumption — it is a risk variable. Build the business so that a policy reversal is painful but survivable, not terminal.
Do not run a cloud migration and a market entry simultaneously against the same capital raise. They are different problems with different timelines and different risk profiles. Doing them concurrently means neither gets done well, and you end up with a product that is neither here nor there at the moment you most need a clean story for US enterprise buyers.
US enterprise healthcare sales cycles are not delays. Mid-market deals can take nine months. State and federal government-adjacent contracts routinely take 18–36 months. Build the revenue model and the cash runway around those numbers. If the runway cannot accommodate the real cycle length, the capital plan is wrong — and raising more capital to fund a model that doesn’t work just delays the reckoning.
Before any US listing or major capital raise built on a US growth thesis, get an independent assessment of whether the capital being raised is adequate for the US competitive battle being funded. NZ investor expectations and US market capital requirements are calibrated to very different realities. The gap between them is where NZ companies run out of money.
Orion Health’s structural mistakes were identifiable before the IPO. A US Entry Architecture engagement would have surfaced four specific design problems: the capital raise was insufficiently sized for the competitive environment; the revenue thesis depended on a single policy scenario; the sales cycle assumptions were calibrated to NZ enterprise norms, not US healthcare procurement timelines; and the cloud migration and market entry were being run concurrently against the same capital with no contingency if either took longer than planned.
None of those are unusual problems. They appear in some form in almost every NZ-to-US expansion. What makes Orion unusual is the scale of the capital destruction when they compound — NZ$70 million in net losses, a 79% share price collapse, 690 jobs eliminated, and the sale of the company’s best asset to fund a battle the remaining capital could not win.
The US Entry Diagnostic exists to surface these problems before they become irreversible. Not to validate the plan — to find the structural flaw in it before the capital is committed that makes the flaw expensive.
“The contracts were coming. They were just taking longer than expected.” — Every quarterly earnings call, 2015–2018. That framing is not wrong. But it is also not a capital plan.”
— PIVOTAL CATALYST VERDICT
FREQUENTLY ASKED
Could Orion Health have succeeded in the US with better preparation?
Yes — the underlying market and product were real. The failure was structural, not conceptual. With a US-calibrated capital plan, a policy-hedged revenue model, enterprise-realistic sales cycle assumptions, and sequenced product migration before market launch, the outcome could have been materially different. The US healthcare interoperability market still exists and is still underserved.
Was the Trump administration’s ACA policy the cause of Orion’s failure?
It was the accelerant, not the cause. The structural problems — undercapitalisation relative to Epic and Cerner, unrealistic sales cycle modelling, concurrent cloud migration and market entry — were embedded before the 2016 election. The policy shift removed a revenue tailwind the model had been built around, exposing the underlying fragility faster than it would otherwise have surfaced.
What does “sales cycle underestimation” actually cost in US healthcare?
In a public company context: it costs you your guidance credibility. Orion told investors the revenue was “coming” across multiple consecutive periods. Each missed forecast eroded trust in management, suppressed the share price, increased the cost of future capital raises, and extended the timeline to profitability. The cash burned in the gap between projected and actual close dates is the most expensive discovery a NZ company can make in US enterprise healthcare.
Go In Knowing
The US Entry Diagnostic delivers a structurally sound plan to enter the US before you invest $500,000 in painful mistakes.
Book the Paid Diagnostic$10,000 NZD. Credited in full toward any engagement.